Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock Has Consensus Price Target of $40.00

Lyell Immunopharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts have a “Moderate Buy” consensus on Lyell Immunopharma, with six buy ratings, one strong buy, one hold and one sell among nine analysts. Their average 12-month price target is $40.
  • Shares opened at $13.80; the company reported quarterly loss per share of $1.86, better than the $2.01 loss analysts expected, while revenue was $0.
  • Major shareholder Arch Venture Partners acquired about 2.32 million shares for roughly $25 million at an average price of $10.77 per share.
  • Interested in Lyell Immunopharma? Here are five stocks we like better.

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $40.00.

A number of equities analysts recently weighed in on LYEL shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Lyell Immunopharma in a research report on Thursday, October 15th. Stifel Nicolaus began coverage on shares of Lyell Immunopharma in a report on Thursday, August 6th. They set a "buy" rating and a $36.00 price objective for the company. Needham & Company LLC restated a "buy" rating and set a $44.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, November 3rd. Royal Bank Of Canada set a $34.00 price target on shares of Lyell Immunopharma in a research report on Friday, August 14th. Finally, Citigroup reissued a "market outperform" rating on shares of Lyell Immunopharma in a report on Friday, August 14th.

Get Our Latest Report on LYEL

Lyell Immunopharma Price Performance

Lyell Immunopharma stock opened at $13.80 on Friday. The stock's 50 day moving average price is $11.08 and its 200 day moving average price is $16.14. Lyell Immunopharma has a 1-year low of $7.20 and a 1-year high of $45.00. The company has a market cap of $339.34 million, a PE ratio of -1.10 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($2.01) by $0.15. The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative return on equity of 107.62% and a negative net margin of 1,701,066.75%. On average, equities research analysts anticipate that Lyell Immunopharma will post -6.88 EPS for the current fiscal year.

Insiders Place Their Bets

In other Lyell Immunopharma news, major shareholder Arch Venture Partners Ix, Llc acquired 2,321,262 shares of the business's stock in a transaction on Wednesday, November 4th. The stock was purchased at an average price of $10.77 per share, with a total value of $24,999,991.74. Following the acquisition, the insider directly owned 3,747,790 shares of the company's stock, valued at approximately $40,363,698.30. This trade represents a 162.72% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Venture Fund Xiii L.P. Arch bought 2,321,262 shares of Lyell Immunopharma stock in a transaction on Wednesday, November 4th. The stock was acquired at an average cost of $10.77 per share, for a total transaction of $24,999,991.74. Following the acquisition, the insider owned 3,747,790 shares in the company, valued at approximately $40,363,698.30. This represents a 162.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders sold 2,100 shares of company stock worth $28,757. Insiders own 6.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ieq Capital LLC purchased a new position in Lyell Immunopharma during the third quarter worth about $102,000. Allspring Global Investments Holdings LLC boosted its stake in Lyell Immunopharma by 4.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 16,824 shares of the company's stock worth $158,000 after purchasing an additional 679 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma in the first quarter worth approximately $445,000. Bank of New York Mellon Corp purchased a new stake in Lyell Immunopharma in the second quarter worth about $347,000. Finally, Empowered Funds LLC purchased a new position in shares of Lyell Immunopharma in the third quarter worth $246,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

About Lyell Immunopharma

(Get Free Report)

Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells' ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company's investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient's own immune cells, which are modified or selected and expanded before being administered as a potential treatment.

Recommended Stories

Analyst Recommendations for Lyell Immunopharma (NASDAQ:LYEL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Lyell Immunopharma Right Now?

Before you consider Lyell Immunopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.

While Lyell Immunopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines